940284-18-4 Usage
General Description
2-(Methylthio)pyrimidine-5-boronic acid pinacol ester is a chemical compound with the molecular formula C11H16BNO2S. It is a boronic acid ester derivative of methylthiopyrimidine. 2-(METHYLTHIO)PYRIMIDINE-5-BORONIC ACID PINACOL ESTER is often used as a reagent in organic synthesis, particularly for the preparation of pharmaceutical intermediates and agrochemicals. It is known for its ability to form stable complexes with a variety of organic compounds, making it a useful building block for the synthesis of complex organic molecules. Additionally, its boronic acid functionality allows for the selective modification of other molecules in the presence of functional groups such as alcohols and amines.
Check Digit Verification of cas no
The CAS Registry Mumber 940284-18-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,4,0,2,8 and 4 respectively; the second part has 2 digits, 1 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 940284-18:
(8*9)+(7*4)+(6*0)+(5*2)+(4*8)+(3*4)+(2*1)+(1*8)=164
164 % 10 = 4
So 940284-18-4 is a valid CAS Registry Number.
940284-18-4Relevant articles and documents
COMPOUNDS AS DGAT-1 INHIBITORS
-
Page/Page column 42; 43, (2013/09/12)
Described herein are compounds of formula I. The compounds of formula I act as DGAT1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.
PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS
-
Page/Page column 110, (2010/04/03)
Novel compounds of structure Formula (I) or an enantiomer, a diastereomer, or a pharmaceutically acceptable salt thereof, wherein Z, R1, R2, R21, T1, T2, T3 and T4 are defined herein, are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy. Thus, the disclosure also concerns compositions comprising these novel compounds and methods of treating diseases or conditions related to the activity of the GPR119 G protein-coupled receptor by using any of these novel compounds or a composition comprising any of such novel compounds.
